The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins ...

It's the superstars of one of B&T's favourite channels - brand experience. Or brand experience with the free sample.

Donald Trump has nominated vocal vaccine sceptic and former Democrat Robert Kennedy Jr as head of the US Department of Health and Human Services, the latest in a series of controversial picks for top ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Biogen will retain its commercial rights to ... The marketed biosimilars are versions of big-selling brands, including Amgen's Enbrel (etanercept), AbbVie's Humira (adalimumab), Johnson ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Last year, Polpharma Biologics and Sandoz won a patent challenge in Europe that resulted in revocation of a key patent on Tysabri in the EU, slashing Biogen's protection for the brand by more than ...